Final Medicare ACO Rule Rejects Pharma Industry Requests For Rx Access Protections
This article was originally published in The Pink Sheet Daily
Executive Summary
Final rule on Medicare accountable care organizations created under the Affordable Care Act is released Oct. 20.
You may also be interested in...
ACOs Can’t Tap Into 340B Drug Discounts Provided To Member Safety Net Facilities, HRSA Clarifies
The clarification could answer biopharma industry concerns about how 340B rules fit in the new Medicare accountable care organization program; HRSA also advises that drug shortage allocation plans may not discriminate against 340 providers.
CMS Interested In Part D Plan Collaboration With Medicare ACOs
In a draft version of its annual instructions to Part D plans, CMS says it is seeking feedback from Part D sponsors and other stakeholders on “possible strategies for achieving better coordination” between stand-alone Medicare Part D plans and accountable care organizations to improve pharmacy care.
ACOs Get In Gear, Accelerating Biopharma’s Value Imperative
Pharmaceutical companies have been reluctant to discuss their accountable care organization strategies, but the 32 “Pioneer” ACOs created this year could impact the way pharma develops and commercializes its drugs, and their influence will be felt well beyond their current Medicare remit.